Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to Strong-Buy at DZ Bank

Posted by on May 21st, 2026

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was upgraded by research analysts at DZ Bank from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

BAYRY has been the subject of several other reports. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Bayer Aktiengesellschaft presently has a consensus rating of “Buy”.

Check Out Our Latest Stock Report on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $11.34 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22. The company has a fifty day simple moving average of $11.29 and a 200 day simple moving average of $11.07. The company has a market cap of $44.57 billion, a P/E ratio of -17.72, a P/E/G ratio of 3.52 and a beta of 0.62. Bayer Aktiengesellschaft has a 1 year low of $6.69 and a 1 year high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. The business had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

Read More

Analyst Recommendations for Bayer Aktiengesellschaft (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.